CORRESPONDENCE
Figure 1
Amplification plots obtained using real-time quantitative PCR and two different preparations of TEL-AML1 primers. Samples C5-C6 and E5-E6 are duplicate amplifications of 0.1 ng total RNA from the TEL/AML1 expressing cell line Reh with non-purified (C5-C6) or highly purified (E5-E6) primers. The sequences of the primers and hybridization probes for TEL/AML1 were as follows: upper primer 5Ј-CAA CGC CTC GCT CAT CTT GCC-3Ј lower primer 5Ј-CAA CGC CTC GCT CAT CTT GCC-3Ј, Taqman probe 5Ј-CAA GCA CGA GCC GCC GCT TCA CGC-3'; for TBP gene sequences were as previously reported in Bièche et al. 4 Primers and probe sequences used for realtime PCR amplification of TEL/AML1 gene were chosen to recognize both major transcripts present in virtually all previously described cases of TEL/AML1 fusion. units of TEL/AML1 target message when the PCR reaction was conducted with highly purified primers rather than non-purified primers. This led to a gain in sensitivity equivalent to at least a four-fold increase as in the example given.
Reh cells express the two major fusions transcripts variants resulting from the alternative splicing of AML1 exon 2 at levels similar to those observed in virtually all diagnostic samples so far analyzed. Therefore, we chose total RNA from Reh cell line as a standard for TEL/AML1 quantitation. Quantitation of fusion transcripts in unknown samples can then simply be done by measuring the sample's Ct (threshold cycle) and by using a standard curve constructed either (1) by serial dilutions of 1 g of Reh cell line RNA-equivalent cDNA into 1ϫ RT buffer or, to reproduce more closely clinical sample analysis, (2) with serial dilutions of 1 g of Reh cell line RNA in a constant amount of mouse RNA, prior to cDNA synthesis. For each standard curve the amounts of the diluted total Reh RNA or cDNA equivalent varied from 100 to 0.01 ng. In both cases we found a strong linear relationship between the Ct and the starting copy number of the TEL/AML1 transcripts (R 2 у 0.99) over a range of at least four orders of magnitude. Also, the PCR efficiency of TEL/AML1 amplification did not differ significantly with the two methods, as indicated by the slope of the curves obtained with the RNA and cDNA point dilutions (−3.76 and −3.66 corresponding to a PCR efficiency value (E) of 84% and 87% respectively). The TEL/AML1 fusion transcripts could be detected after 10 4 -fold dilution of 1 g of Reh total RNA in mouse total RNA, which is equivalent to 10 pg of target RNA. The average Ct of the TEL/AML1 target at this dilution was 37.8 with a within-run coefficient of variation (CV) of Ct values varying from 0.8 to 2.4 in different PCR runs. Thus the sensitivity of the method was comparable to that of conventional end-point RT-PCR used for diagnostic purposes. At lower RNA concentration (5 × 10 4 and 10 5 -fold dilutions), positive samples were still detected but the variation among sample replicates became too high for accurate measurement. Indeed, as the Ct values of TEL/AML1 increased to over 40, the CV among sample replicates was greater than 2.5%, indicating that the quantitation of positive results was not reliable. As the CV for Ct values of triplicates samples indicates the reproducibility of the measure, the limit of accurate quantitation can be easily deduced from the CV.
Because the limit of target detection and quantitation was not the same, we introduced a 'reference sample' to define the quantitation limit. The reference sample represents the smallest amount of target messenger that can be detected and accurately quantified. This limit was a dilution corresponding to 50 pg of human cell line Reh total RNA in 1 g of mouse RNA. At this concentration the Ct values of TEL/AML1 varied between 35 and 36, but the within-run variation of the averaged Ct was always below 2%. Moreover, the reference sample provides a quantitative internal control, both for the efficiency of the RT-PCR procedure and for RNA and cDNA recovery ( Figure 2) .
Variations in starting amount of total RNA or RT efficiency among samples were taken into account by parallel amplification of an endogenous mRNA control. We chose the TBP gene (TATA box-binding protein, a component of the DNA-binding protein complex TFIID) as endogenous control because it is an ubiquitous transcription factor whose expression is constant in normal tissues and is similar to TEL/AML1 expression in the cell line Reh (TBP-Ct and TEL-AML-Ct Ͻ22, for 100 ng of total RNA, with a within-run CV 2%). We rejected PBGD gene because of its low expression level compared to TEL/AML1. The endogenous control should be expressed at an adequate level (ideally, at a level equivalent to the standard) in order to avoid underestimating positive samples and obtaining false-negative results. For each experimental sample, the amount of target and endogenous reference was determined from the standard curve. Then the target amount was divided by the endogenous reference amount to obtain a normalized target value.
We validated the RQ-RT-PCR assay on bone marrow (BM) samples from four patients (Table 1) . Our study was not aimed to assess the clinical value of TEL/AML1 detection during CR but rather to evaluate the potential use of RQ-RT-PCR for quantitation of MRL to have prognostic significance. Although this small number of patients does not allow us to draw firm clinically relevant conclusions the comparison
Figure 2
Outline of TEL/AML1 quantitation procedure. RT-PCR procedure was validated by using a reference sample. The reference sample defines the lowest amount of target that can be accurately quantified (ie the within-run CV for the averaged Ct values of TEL/AML1 should be lower than 2%). In our hands this limit corresponded to TEL/AML-Ct values comprised between 35 and 36 for 50 pg of standard total RNA. RNA extraction procedure was validated only when TBP-Ct value was Ͻ30. -45 ), all the patients had a reduction in TEL/AML1 values of at least two logs. Interestingly, the highest values were found in patients UPN3 and UPN4 who subsequently relapsed. Furthermore these patients developed detectable and quantifiable disease 3 to 5 months after entering the first CR, whereas patients UPN1 and UPN2 had TEL/AML1 below the quantitation limit. Patients UPN3 and UPN4 were consistently MRL positive. We have shown that our RQ-RT-PCR assay can be used to calculate a slope of disease response to therapy for each patient. Thus, it might be possible to compare directly the relative efficacy of treatment regimens given to patients in different institutions, and therapy could conceivably be adapted to the individual response. The high efficiency and throughput of real-time PCR, as well as the absence of post-PCR manipulations, make Taqman methodology eminently suitable for routine large-scale application and an inter-laboratories standardization.
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